13F Holdings
中文EN

SPRO Spero Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1701108 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY2.5%
TTM net income YoY32.7%
TTM EPS YoY36.7%
Revenue 3-yr CAGR-18.8%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-67.3%
Net margin-71.0%
FCF margin—
EBITDA margin—

Returns

ROE-216.4%
ROA-35.9%
ROIC (approx.)—
Asset turnover0.51x

Leverage & solvency

Liabilities / assets99.3%
Debt / equity0.00x
Current ratio1.92x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.37x
Accruals ratio13.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$0$0$258,000$41.30M$5.44M$14.19M$5.87M$15.04M
R&D expense$3.20M$3.43M$2.91M$5.59M$8.60M$10.67M$13.61M$28.84M
SG&A expense$3.72M$6.49M$4.89M$4.30M$4.17M$5.88M$6.82M$7.06M
Operating income-$41.91M-$9.93M-$7.54M$31.41M-$7.92M-$2.44M-$14.73M-$21.73M
Income tax———$261,000$0——$290,000
Net income-$44.28M-$9.55M-$7.20M$31.52M-$7.38M-$1.70M-$13.87M-$20.89M
EBITDA———$31.41M-$7.92M——-$21.73M
EPS (basic)-0.76-0.16-0.13—-0.13-0.03-0.25—
EPS (diluted)-0.76-0.16-0.13—-0.13-0.03-0.25—
Weighted avg. shares (diluted)58.23M57.97M57.28M—56.28M56.03M55.38M—
Banking
Net interest income$2.37M———-$532,000———
Balance sheet
Cash & equivalents$107.93M$50.77M$56.13M$40.27M$48.62M$31.19M$48.89M$52.89M
Current assets$109.23M$51.58M$57.61M$67.29M$52.32M$59.40M$74.71M$107.28M
PP&E, net———————$0
Total assets$110.03M$52.77M$59.02M$68.92M$54.17M$62.12M$77.71M$110.54M
Current liabilities$56.96M$8.43M$5.49M$8.87M$13.65M$14.95M$29.16M$49.07M
Total liabilities$109.25M$8.56M$6.09M$9.90M$27.68M$29.29M$43.90M$64.42M
Shareholders' equity$781,000$44.20M$52.93M$59.02M$26.49M$32.83M$33.81M$46.12M
Shares outstanding58.24M58.15M57.89M56.41M56.31M56.19M55.90M54.59M
Cash flow statement
Operating cash flow-$42.61M-$5.36M$15.86M-$8.35M$17.42M-$17.69M-$4.00M-$23.40M
Financing cash flow———————$0
Depreciation & amortization———$0$0——$0
Stock-based compensation$855,000$822,000$1.11M$1.01M$1.05M$714,000$1.56M$1.50M

Free plan shows the latest 8 periods; Pro shows all 43 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.